Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 Combination Therapy in TNBC
NCT07045311Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of JS207 in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2025; status: recruiting.
02
Drugs
JS207
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07045311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07045311.